Every material Form 8-K Lipocine Inc. has filed with the SEC since October 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Lipocine reported a third-quarter 2026 net loss of $0.7 million, or $0.08 per diluted share, down from a net loss of $3.2 million, or $0.59 per share, a year earlier. Revenue rose to $2.3 million from $115,000, driven by $2.1 million of license and collaboration revenue. Cash and marketable securities were $21.5 million at September 30, 2026, and about $28.5 million at November 4, 2026 (unaudited).
Q3 2026 net loss was $0.7 million ($0.08 per diluted share), compared with $3.2 million ($0.59 per share) in Q3 2025.
Q3 2026 total revenue was $2.3 million, including $2.1 million of license and collaboration revenue and $190,000 of TLANDO royalty revenue.
Cash, cash equivalents and marketable investment securities were $21.5 million at September 30, 2026, and about $28.5 million at November 4, 2026 (unaudited).
Nine-month net loss was $7.0 million ($0.90 per share), versus $7.3 million ($1.35 per share) a year earlier.
Lipocine Inc. filed an 8-K reporting that it has updated the corporate presentation it uses when meeting with investors, analysts and others. The updated presentation is attached as Exhibit 99.1; the filing does not describe its contents or any financial results.
Lipocine updated its corporate presentation used with investors, analysts and others.
The presentation is filed as Exhibit 99.1 to the 8-K.
The report is dated October 20, 2026 and signed by CEO Mahesh V. Patel.
Health Canada approved TLANDO, a Lipocine oral testosterone product, for testosterone replacement therapy in adult males, announced October 7, 2026. The approval is held through licensing partner Verity Pharma, which plans a Canadian launch by the end of 2026 and holds exclusive North American commercial rights.
Approval covers adult males with conditions tied to testosterone deficiency or absence (male hypogonadism).
Verity Pharma holds exclusive commercial rights to TLANDO in North America and plans a Canadian launch by the end of 2026.
The filing cites more than 700,000 annual TRT prescriptions in Canada, but gives no sales or revenue projection for TLANDO in Canada.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Lipocine Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →